INDP
NASDAQIndaptus Therapeutics
$2.02
-0.08 (-3.57%)
2026-06-09 00:00
Healthcare
Biotechnology
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$414.5M
P/E Ratio
N/A
52W Low
52W High
$0.93
$8.57
Volume
1.6M
Analyst Rating
Hold
Target: $10
10 Analyst Ratings
Strong Buy
0
Buy
0
Hold
10
Sell
0
Price Target Range
Low: $10
Avg: $10
High: $10
About Indaptus Therapeutics
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The com...
Employees
5
Website
indaptusrx.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | N/A | N/A% | -$20.8M | -$14.8M |
| 2024 | N/A | N/A% | -$15.0M | -$12.3M |
| 2023 | N/A | N/A% | -$15.4M | -$13.4M |
| 2022 | N/A | N/A% | -$14.3M | -$12.9M |
| 2021 | N/A | N/A% | -$7.7M | -$11.3M |
| 2026 Q1 | N/A | N/A% | -$2.5M | -$7.0M |
| 2025 Q4 | N/A | N/A% | -$8.1M | -$3.2M |
| 2025 Q3 | N/A | N/A% | -$3.0M | -$3.1M |
| 2025 Q2 | N/A | N/A% | -$5.2M | -$4.0M |
| 2025 Q1 | N/A | N/A% | -$4.5M | -$5.0M |
| 2024 Q4 | $1K | -283780.3% | -$4.1M | -$3.4M |
| 2024 Q3 | N/A | N/A% | -$3.1M | -$2.5M |
| 2024 Q2 | N/A | N/A% | -$4.0M | -$2.5M |